Literature DB >> 25380742

Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall.

I Shaikh1, W Aston, G Hellawell, D Ross, S Littler, D Burling, M Marshall, J M A Northover, A Antoniou, J T Jenkins.   

Abstract

BACKGROUND: Complete pathological resection of locally advanced or recurrent rectal and anal cancer is regarded as one of the most important determinants of oncological outcome. Disease in the lateral pelvic sidewall has been considered a contraindication for pelvic exenteration surgery owing to the significant likelihood of incomplete resection.
METHODS: We describe a novel technique (ELSiE) to resect disease involving the lateral pelvic sidewall. Patient demographics, post-operative histology, length of hospital stay and complications were collected from prospectively maintained electronic patient database.
RESULTS: During 2011-2013, six patients underwent pelvic exenteration surgery with the ELSiE approach. All patients had R0 resection. Three patients required sciatic nerve excision. Four patients developed post-operative complications although no major complications occurred.
CONCLUSIONS: Patients with locally advanced and recurrent cancer involving the lateral pelvic sidewall may be rendered suitable for potentially curative radical resection with a modification in the approach to the lateral pelvic sidewall. Our pilot series seems to indicate that our novel technique (ELSiE) is feasible, safe and yields high rates of complete pathological resection.

Entities:  

Mesh:

Year:  2014        PMID: 25380742     DOI: 10.1007/s10151-014-1234-9

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  36 in total

1.  Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer.

Authors:  A Wibe; P R Rendedal; E Svensson; J Norstein; T J Eide; H E Myrvold; O Søreide
Journal:  Br J Surg       Date:  2002-03       Impact factor: 6.939

Review 2.  Salvage of pelvic recurrence of colorectal cancer.

Authors:  Kimberly A Varker; Harold J Wanebo
Journal:  J Surg Oncol       Date:  2010-06-15       Impact factor: 3.454

3.  Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer.

Authors:  K Yamada; T Ishizawa; K Niwa; Y Chuman; S Akiba; T Aikou
Journal:  Br J Surg       Date:  2001-07       Impact factor: 6.939

4.  Complications and outcome of external hemipelvectomy in the management of pelvic tumors.

Authors:  J P Apffelstaedt; D L Driscoll; J E Spellman; A F Velez; J F Gibbs; C P Karakousis
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

5.  Prediction of residual disease or distant metastasis after resection of locally recurrent rectal cancer.

Authors:  Yukihide Kanemitsu; Takashi Hirai; Koji Komori; Tomoyuki Kato
Journal:  Dis Colon Rectum       Date:  2010-05       Impact factor: 4.585

6.  Preliminary experience with external hemipelvectomy for locally advanced and recurrent pelvic carcinoma.

Authors:  M B Nielsen; P Rasmussen; J Keller; S Laurberg
Journal:  Colorectal Dis       Date:  2012-02       Impact factor: 3.788

7.  Pelvic exenteration with en bloc iliac vessel resection for lateral pelvic wall involvement.

Authors:  Kirk K S Austin; Michael J Solomon
Journal:  Dis Colon Rectum       Date:  2009-07       Impact factor: 4.585

8.  Hemipelvectomy: a changing perspective for a rare procedure.

Authors:  Christopher R Baliski; Norman S Schachar; J Gregory McKinnon; Gavin C Stuart; Walley J Temple
Journal:  Can J Surg       Date:  2004-04       Impact factor: 2.089

9.  Unresectable colorectal cancer can be cured with multimodality therapy.

Authors:  Kellie L Mathis; Heidi Nelson; John H Pemberton; Michael G Haddock; Leonard L Gunderson
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

10.  Rectal cancer recurrence: factors and mechanisms.

Authors: 
Journal:  Colorectal Dis       Date:  2000-05       Impact factor: 3.788

View more
  9 in total

1.  R0 resection, not surgical technique, is the key consideration in pelvic exenteration surgery.

Authors:  O J Warren; M J Solomon
Journal:  Tech Coloproctol       Date:  2014-12-28       Impact factor: 3.781

2.  Laparoscopic pelvic sidewall dissection with combined resection of internal iliac vessels for local recurrence of rectal cancer.

Authors:  S Hasegawa; G Nishikawa; K Hida; K Kawada; Y Sakai
Journal:  Tech Coloproctol       Date:  2015-07-26       Impact factor: 3.781

Review 3.  Surgery for Locally Recurrent Rectal Cancer: Tips, Tricks, and Pitfalls.

Authors:  Satish K Warrier; Alexander G Heriot; Andrew Craig Lynch
Journal:  Clin Colon Rectal Surg       Date:  2016-06

4.  [Resection of recurrent rectal cancer].

Authors:  I Gockel; C Pommer; S Langer; B Jansen-Winkeln
Journal:  Chirurg       Date:  2018-08       Impact factor: 0.955

5.  Transperineal retropubic approach in total pelvic exenteration for advanced and recurrent colorectal and anal cancer involving the penile base: technique and outcomes.

Authors:  A M Mehta; G Hellawell; D Burling; S Littler; A Antoniou; J T Jenkins
Journal:  Tech Coloproctol       Date:  2018-10-10       Impact factor: 3.781

Review 6.  Locally advanced rectal cancer: management challenges.

Authors:  R F Kokelaar; M D Evans; M Davies; D A Harris; J Beynon
Journal:  Onco Targets Ther       Date:  2016-10-13       Impact factor: 4.147

7.  Extended pelvic side wall excision for locally advanced rectal cancers.

Authors:  Irshad A Shaikh; John T Jenkins
Journal:  World J Gastroenterol       Date:  2017-12-14       Impact factor: 5.742

8.  Believable or not believable MRAM.

Authors:  David Cibula
Journal:  Gynecol Oncol Rep       Date:  2017-07-13

Review 9.  Advances in surgical management for locally recurrent rectal cancer: How far have we come?

Authors:  Daniel Jin-Keat Lee; Peter M Sagar; Gaitri Sadadcharam; Kok-Yang Tan
Journal:  World J Gastroenterol       Date:  2017-06-21       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.